Arcutis & Sato have signed a strategic collaboration & licensing agreement to develop, manufacture & commercialize topical Zoryve for dermatological diseases such as plaque psoriasis, seborrheic dermatitis & atopic dermatitis in Japan
Under the collaboration, Arcutis is entitled to receive $25M upfront and additional $40M for achieving regulatory & sales milestones plus tiered, low double-digit percentage royalties
Sato gains exclusive rights to develop, manufacture & commercialize Zoryve cream, foam & other topical presentations in Japan while Arcutis will handle the development & commercialization of its cream & foam formulation across the globe (excl. Greater China & Southeast Asia)
Ref: Arcutis | Image: Arcutis
Related News:- Arcutis Reports the US Launch of Zoryve (roflumilast) Topical Foam, 0.3%, for Treating Seborrheic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
